JLE

Hématologie

MENU

End-of-life platelet transfusion in haematological malignancies: a review Article à paraître

  • [1] Gaydos L., Freireich E., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukaemia. N Engl J Med. 1962;266:905-909.
  • [2] Estcourt L.J., Stanworth S.J., Murphy M.F. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol. 2011;154:425-440.
  • [3] Michallet M. Transfusion de plaquettes : produits, indications. Agence Française de Sécurité Sanitaire des Produits de Santé; 2003.
  • [4] Malouf R., Ashraf A., Hadjinicolaou A.V., Doree C., Hopewell S., Estcourt L.J. Comparison of a therapeutic-only prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. Cochrane Database Syst Rev. 2018;5:CD012342. versus5
  • [5] Eikenboom J.C.J., van Wordragen R., Brand A. Compliance with prophylactic platelet transfusion trigger in haematological patients. Transfus Med. 2005;15:45-48.
  • [6] Bordessoule D., Jaulmes D., Lévy-Soussan M. Réflexion sur la prise en charge des patients atteints d’hémopathies malignes nécessitant des transfusions itératives. Hématologie. 2012;18:190-193.
  • [7] Transfusion de plaquettes : produits, indications. Méthode Recommandations pour la pratique clinique. France: HAS et ANSM; 2015. Haute Autorité de Santé et Agence Nationale du Médicament
  • [8] Uceda Torres M.E., Rodríguez J.N., Sánchez Ramos J.L., Alvarado Gómez F. Transfusion in palliative cancer patients: a review of the literature. J Palliat Med. 2014;17:88-104.
  • [9] Dasch B., Kalies H., Feddersen B., Ruderer C., Hiddemann W., Bausewein C. Care of cancer patients at the end of life in a German university hospital: a retrospective observational study from 2014. PLoS One. 2017;12:e0175124.
  • [10] Hoell J., Warfsmann J., Balzer S., Borkhardt A., Janssen G., Kuhlen M. End-of-life care in children with hematologic malignancies. Oncotarget. 2017;8:89939-89948.
  • [11] Argyrou A. 21st Congress of the European Hematology Association Copenhagen, Denmark, June 9-12, 2016. Haematologica. 2016;101:645. S1
  • [12] Brück P., Pierzchlewska M., Kaluzna-Oleksy M. Dying of hematologic patients--treatment characteristics in a German University Hospital. Support Care Cancer. 2012;20:2895-2902.
  • [13] Fletcher S.A., Cronin A.M., Zeidan A.M. Intensity of end-of-life care for patients with myelodysplastic syndromes: findings from a large national database. Cancer. 2016;122:1209-1215.
  • [14] Lindquist K.J., Danese M.D., Mikhael J., Knopf K.B., Griffiths R.I. Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol. 2011;22:1181-1188.
  • [15] Wang W.S., Ma J.D., Nelson S.H. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018;26:1927-1931.
  • [16] Cheng B.H.W., Sham M.M.K., Chan K.Y., Li C.W., Au H.Y. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32:221-225.
  • [17] Lowe J.R., Yu Y., Wolf S., Samsa G., LeBlanc T.W. A cohort study of patient-reported outcomes and healthcare utilization in acute myeloid leukemia patients receiving active cancer therapy in the last six months of life. J Palliat Med. 2018;21:592-597.
  • [18] Sirianni G., Perri G., Callum J., Gardner S., Berall A., Selby D. A retrospective chart review of transfusion practices in the palliative care unit setting. Am J Hosp Palliat Care. 2018;36:185-190.
  • [19] Kodama Y., Matsumura T., Yamaguchi T. Age, gender, will and use of home-visit nursing care are critical factors in home care for malignant diseases; a retrospective study involving 346 patients in Japan. BMC Palliat Care. 2011;10:17.
  • [20] Capodanno I., Tamagnini E., Alfieri P., Codeluppi K., Luminari S., Merli F. Home care of acute leukaemia patients: from active therapy to end-of-life and palliative care. The 3-year experience of a single centre. Eur J Haematol. 2019;102:424-431.
  • [21] Kihara R., Ishiguri Y., Ueda N. Effect of speciallist palliative care service on end-of life care in patients with hematologic malignancies. Blood. 2018;132:2242-12242.
  • [22] Bastard C., Bordessoule D., Casassus P. Les limitations thérapeutiques en hématologie : réflexions et propositions éthiques de la Société Française d’Hématologie. Hématologie. 2005;11:71-79.
  • [23] Earle C.C., Neville B.A., Landrum M.B. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care. 2005;17:505-509. 6
  • [24] Odejide O.O. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10:396-403.
  • [25] Epstein A.S., Goldberg G.R., Meier D.E. Palliative care and hematologic oncology: the promise of collaboration. Blood Rev. 2012;26:233-239.
  • [26] Mannis G.N., McNey L.M., Gupta N.K., Gross D.M. The transfusion tether: bridging the gap between end-stage hematologic malignancies and optimal end-of-life care. Am J Hematol. 2016;91:364-365.
  • [27] LeBlanc T.W., El-Jawahri A. Hemato-oncology and palliative care teams: is it time for an integrated approach to patient care? Curr Opin Support Palliat Care. 2018;12:530-537.
  • [28] Howell D.A., Shellens R., Roman E., Garry A.C., Patmore R., Howard M.R. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25:630-641.
  • [29] Gergi M., Soriano-Pisaturo M.A. Palliative care issues for transfusion-dependent patients #359. J Palliat Med. 2018;21:1359-1360.
  • [30] Smith L.B., Cooling L., Davenport R. How do I allocate blood products at the end of life? An ethical analysis with suggested guidelines: end of life blood product allocation. Transfusion. 2013;53:696-700.
  • [31] Sherbeck J.P., Boss R.D. Ethical questions about platelet transfusions at the end of life. AMA J Ethics. 2016;18:764-770.
  • [32] Wandt H., Ehninger G., Gallmeier W.M. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001;6:446-450.
  • [33] Estcourt L.J. Why has demand for platelet components increased? A review. Transfus Med. 2014;24:260-268.
  • [34] Rapport d’activité 2017. Paris: Établissement Français du Sang; 2018. L’EFS., en chiffre
  • [35] Goubran H., Seghatchian J., Prokopchuk-Gauk O. Reflections on multiple strategies to reduce transfusion in cancer patients : A joint narrative. Transfus Apheresis Sci. 2017;56:322-329. 3
  • [36] Estcourt L.J., Birchall J., Allard S. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176:365-394.
  • [37] Bordessoule D., Moreau S. Soins palliatifs en hématologie. Paris: Dunod; 2014.
  • [38] Dyer C., Alquist C.R., Cole-Sinclair M. A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. Vox Sang. 2018;113:251-259.
  • [39] Pepion C. Insuffisance rénale chronique et syndrome hémorragique. Sang Thromb Vaiss. 2003;15:442-448.
  • [40] Kennel C., Rey S., Dubosc-Marchenay N. Modélisation d’un plan personnalisé de soins transfusionnel pour les patients atteints de myélodysplasies dépendant des transfusions. Transfus Clin Biol. 2013;20:295-369.